Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
Phase 3positiveIvonescimabDurvalumabPositive
AI Analysis
Summary
Akeso's ivonescimab plus chemotherapy demonstrated a significant overall survival benefit versus durvalumab plus chemotherapy in the HARMONi-GI1 Phase 3 trial for first-line biliary tract cancer, meeting the primary endpoint.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
HARMONi-GI1 trial met primary endpoint, demonstrating significant overall survival benefit for ivonescimab plus chemotherapy versus durvalumab plus chemotherapy
Importance:8/10
Sentiment:
0.85
oncologybiliary tract cancerimmunotherapyPhase 3 datapositive trial results
Related Companies
Read the original article
Published by PR Newswire Biotech on August 25, 2026 9:00 PM